1. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009
2. Higano C, Saad F, Somer B, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Presented at the 2009 Genitourinary Cancers Symposium; February 26–28, 2009; Orlando, Florida.
3. Small E, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Presented at the 2009 Genitourinary Cancers Symposium; February 26–28, 2009; Orlando, Florida.
4. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma;Saad;J Natl Cancer Inst,2002
5. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer;Carducci;Cancer,2007